Is there an impact of treatment with DPP-4 inhibitors on lymphocyte subpopulations in type 2 diabetic patients?

Endokrynologia Polska

Volumn 65, Issue 2, 2014, Pages 78-82

  Strojek, Krzysztof ^a   Górska, Juta ^a   Rokicka, Dominika ^a   Szymborska Kajanek, Aleksandra ^a   Wróbel, Marta ^a   Sȩdek, Łukasz ^a   Szczepański, Tomasz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Diabetes type 2; DPP 4 inhibitors; Lymphocyte subpopulations

Indexed keywords

SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NITRILE; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; CD26+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD45RA+ T LYMPHOCYTE; CD45RO+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; RANDOMIZATION;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; RANDOM ALLOCATION; SITAGLIPTIN PHOSPHATE;

EID: 84901396915     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2014.0011     Document Type: Article

References (19)

1. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053. (Pubitemid 38579764)
2. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 (Suppl. 5): S1-S85.
3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368 (9548): 1696-1705. (Pubitemid 46048557)
4. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940. (Pubitemid 37205571)
5. Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis. JAMA 2007; 298: 194-206. (Pubitemid 47057766)
6. Karagiannis T, Paschos P, Paletas K et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369 doi: 10.1136/bmj.e1369.
7. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006; 29: 1963-1972.
8. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60: 1454-1470. (Pubitemid 44560347)
9. Belle L, Bitencourt PE, de Bona K et al. Expression of CD26 and its association with dipeptidyl peptidase IV activity in lymphocytes of type 2 diabetes patients. Cell Biochem Biophys 2011; 61: 297-302.
10. Dang NH, Morimoto C. CD26: an expanding role in immune regulation and cancer. Histol Histopathol 2002; 17: 1213-1226.
11. Ohnuma K, Dang NH, Morimoto Ch. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends in Immunology 2008; 9: 295-301.
12. Hosono O, Ohnuma K, Dang NH et al. CD26: a key molecule in immune regulation and autoimmune diseases. Mod Rheumatol 2003; 13: 199-204 (Pubitemid 37258786)
13. Richter B, Bandeira-Echtler E, Bergerhoff K et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2008: CD006739.
14. Nishioka T, Shinohara M, Tanimoto N et al. Sitagliptin, a Dipeptidyl Peptidase-IV inhibitor, improves psoriasis. Dermatology 2012; 224: 20-21.
15. White PC, Chamberlain-Shea H, de la Morena MT. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation. J Diabetes Complications 2010; 24: 209-213.
16. Szczepański T, van der Velden V, van Dongen J. Flow-cytometric immunophenotyping of normal and malignant lymphocytes. Clin Chem Lab Med 2006; 44: 775-796.
17. Kalina T, Flores-Montero J, van der Velden VH et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26: 1986-2010.
18. Morimoto C, Schlossman SR. The structure and function of CD26 in the T-cell immune response. Immunologicai Reviews 1998; 161: 55-70.
19. Bengsch B, Seigel B, Flecken T et al. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 2012; 88: 5438-5447.